查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1718350

化療引起的周邊神經病變治療市場按治療類型、給藥途徑、患者年齡層、治療持續時間和最終用戶分類——2025 年至 2030 年全球預測

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Type, Route of Administration, Patient Age Group, Therapy Duration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

化療引起的周邊神經病變治療市場在 2024 年的價值為 9.8584 億美元，預計在 2025 年將成長至 10.6412 億美元，複合年成長率為 8.21%，到 2030 年將達到 15.8361 億美元。

主要市場統計數據
基準年2024年 9.8584億美元
預計2025年 10.6412億美元
預測年份 2030 1,583,610,000美元
複合年成長率（%） 8.21%

化療引起的周邊神經病變(CIPN) 是影響接受癌症治療的患者生活品質的重大挑戰。這份全面的概述探討了 CIPN 治療的現狀，並揭示了不斷發展的實踐和創新研究如何重塑治療方法。對於藥物治療和非藥物治療的細緻理解的需求從未如此強烈。該報告綜合了大量數據和趨勢，研究了治療方法、區域市場動態、主要企業活動和可行的建議，以幫助行業領導者做出策略決策。

由於 CIPN 對患者預後和整體醫療保健成本的直接影響，對其治療的研究正在不斷加強。在這種新形勢下，必須同時採用治療方法和創新治療方法。新興治療方法和可靠的臨床數據正在推動更以患者為中心的模式，從而鼓勵將創新策略整合到既定的臨床方案中。隨著腫瘤學領域的不斷發展，相關人員必須採取前瞻性的觀點，利用最新的市場洞察力來應對治療設計中的當前挑戰和未來機會。

此次聘用為深入研究不斷變化的治療格局、關鍵細分考慮因素以及決定市場的地理和競爭動態奠定了基礎。透過提供從宏觀趨勢到細微細分因素的廣泛分析，本簡報可作為策略指南，旨在為決策者提供所需的資訊，以改善治療結果並推動 CIPN 領域的創新。

改變化療引起的周邊神經病變治療市場

近年來，發生了一些變革，從根本上改變了 CIPN 管理方法。化療和隨後的周邊神經病變的緊迫挑戰引發了研究和開發的激增，導致向個人化多學科治療方法的顯著轉變。從歷史上看，CIPN 一直採用有限的標靶治療進行症狀治療。然而，新的研究成果和技術進步正在整合，以開發更複雜的個人化治療。

創新的非藥物療法因其促進患者康復的能力而越來越受到認可。針灸、物理治療和經皮神經電刺激等手動技術作為傳統藥物治療措施的可行替代或補充，正在穩步發展。與這些策略同時，人們越來越關注藥物治療，例如抗驚厥藥、抗憂鬱症和鴉片類藥物，這引發了關於其功效、安全性和對患者的適用性的進一步爭論。對先進的非藥物療法和最佳化的藥物療法的雙重重視標誌著向整體治療框架的明顯轉變。

最近的策略舉措也透過推廣針對癌症治療的神經系統和全身影響的聯合治療來重新定義護理途徑。臨床醫生擴大根據患者的獨特情況制定治療計劃，而不是僅僅遵循標準化的方案。這種個人化方法依賴藥理學研究和調查方法的突破，以確保治療性介入科學合理並符合以患者為中心的護理模式。

此外，數位健康工具和穿戴式監測系統的進步使臨床醫生能夠即時追蹤治療進展。這種數據主導的洞察力不僅可以提高治療的精確度，而且還鼓勵更積極地應對潛在的副作用。技術創新與臨床專業知識的融合顯然正在重新定義治療格局，開啟一個以自適應、即時、個人化患者照護為特徵的新時代。

CIPN 治療的進步趨勢反映了業界向精準醫療和綜合醫療邁進的更廣泛趨勢。借助新數據和高級分析技術，醫療保健提供者現在能夠更好地管理複雜的治療方法，同時主動管理化療相關的副作用。這種模式轉移不僅改變了患者的治療結果，也為臨床研究和專業實踐設定了新的基準。

推動市場差異化的關鍵細分洞察

詳細的細分分析揭示了影響 CIPN 治療競爭格局和策略前景的幾個關鍵方面。根據治療類型研究將治療方法分為非藥物治療和藥物治療兩類。在非藥物介入中，針灸、物理治療和經皮神經刺激等治療方法已變得越來越重要，因為它們能夠提供症狀管理的替代方法，而沒有藥物治療相關的全身副作用。同時，藥物介入也在不斷發展，特別是針對與 CIPN 相關的潛在神經系統損傷的抗驚厥藥、抗憂鬱症和鴉片類藥物的應用日益廣泛。

根據給藥途徑進一步細分，引入了治療策略的複雜性和個人化。雖然傳統的口服給藥因其便利性而繼續受到青睞，但肌肉注射和靜脈注射等腸外給藥方式為需要快速治療性介入的患者提供了有針對性的給藥選擇。局部給藥也發揮重要作用，它能提供局部緩解，而不會產生廣泛的全身性影響，增加了治療通訊協定的靈活性。對於給藥途徑的詳細考慮凸顯了我們致力於提供針對患者的具體方法以最佳化療效和安全性的承諾。

此外，患者年齡細分可明確區分成人、老年和兒科患者。這種人口統計細分至關重要，因為與年齡相關的生理差異需要採取客製化方法，考慮到新陳代謝、耐受性和患者的整體復原力。由於患者的狀況差異很大，這種細分框架將推動針對特定年齡的治療方法的發展，並強調更精細的臨床指南的必要性。

另一個重要維度是治療持續時間，將介入措施分為長期治療和短期治療。這種細分揭示了個別患者在治療過程中所需的護理的連續性和強度。策略洞察表明，長期治療方案對於患有慢性或難治性疾病的患者非常重要，而短期治療對於急性管理情況有效。了解這些時間細微差別將使相關人員能夠更好地分配資源並設計符合患者需求和臨床結果的治療方法。

最後，透過最終使用者設定（例如居家照護、醫院或專科診所）的區分，可以根據護理環境量身定做干涉措施。在受控的醫院環境中成功實施的治療方法在應用於居家照護或專科門診時可能需要進行調整。這種細分洞察可以深刻地指導有關市場定位、資源分配和網路協調的策略決策。這種多層次的細分確保治療策略不僅滿足廣泛的臨床目標，而且更能滿足不同患者群體的不同需求。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球癌症發生率上升
      • 提高醫療保健專業人員對化療引起的周邊神經病變的認知
      • 全球政府對腫瘤學研究的資助激增
    • 限制因素
      • 藥物開發過程及研發活動高成本
    • 機會
      • 為患有周邊神經病變症狀的患者開發符合人體工學的穿戴式設備
      • 擴大人工智慧技術在神經病變風險評估預測模型開發的應用
    • 任務
      • 化療後神經病變的複雜機制
  • 市場區隔分析
    • 治療類型：抗驚厥藥和抗憂鬱症，具有穩定神經元活動的雙重作用，越來越受到青睞。
    • 最終用戶：擴大CIPN在醫院的應用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章化療引起的周邊神經病變治療市場（依治療類型）

  • 介紹
  • 非藥物治療
    • 針刺
    • 物理治療
    • 經皮電刺激
  • 藥物治療
    • 抗驚厥藥
    • 抗憂鬱症
    • 鴉片類藥物

第7章化療引起的周邊神經病變治療市場（依給藥途徑）

  • 介紹
  • 口服
  • 腸外
    • 肌肉注射
    • 靜脈
  • 局部的

第8章化療引起的周邊神經病變治療市場（依患者年齡層）

  • 介紹
  • 成人
  • 老年人
  • 孩子們

第9章化療引起的周邊神經病變治療市場（依治療持續時間）

  • 介紹
  • 長期治療
  • 短期治療

第 10 章化療引起的周邊神經病變治療市場（依最終用戶）

  • 介紹
  • 居家照護
  • 醫院
  • 專科診所

11.美洲化療引起的周邊神經病變治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區化療引起的周邊神經病變治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲化療引起的周邊神經病變治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • AlgoTherapeutix
  • Amgen Inc.
  • Array BioPharma Inc. by Pfizer Inc.
  • Artelo Biosciences, Inc.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bexion Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Grunenthal GmbH
  • Heron Therapeutics, Inc.
  • Ipsen Pharma
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Neuralace Medical
  • Novartis AG
  • Regenacy Pharmaceuticals LLC
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Serpin Pharma, LLC
  • Takeda Pharmaceutical Company Limited
  • Veloxis Pharmaceuticals, Inc.
Product Code: MRR-1A1A064C04DA

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 985.84 million in 2024 and is projected to grow to USD 1,064.12 million in 2025, with a CAGR of 8.21%, reaching USD 1,583.61 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 985.84 million
Estimated Year [2025] USD 1,064.12 million
Forecast Year [2030] USD 1,583.61 million
CAGR (%) 8.21%

Chemotherapy induced peripheral neuropathy (CIPN) represents a significant challenge that impacts the quality of life for patients undergoing cancer treatments. In this comprehensive summary, we explore the current state of CIPN treatment, underlining how evolving practices and innovative research are reshaping therapeutic approaches. The need for a nuanced understanding of both pharmacological and non-pharmacological treatments has never been greater. This report synthesizes a wealth of data and trends, examining treatment methodologies, regional market dynamics, key company players, and actionable recommendations that support strategic decision-making among industry leaders.

Research into CIPN treatment has intensified, propelled by its direct impact on patient outcomes and overall cost-of-care considerations. In this new landscape, embracing both traditional and breakthrough treatment modalities is essential. Newly emerging therapeutic practices and robust clinical data are driving a more patient-focused paradigm which, in turn, bolsters the integration of innovative strategies into established clinical protocols. As the oncology field continues to evolve, stakeholders must adopt a forward-looking perspective and leverage the latest market insights to address both current challenges and future opportunities in treatment design.

This introduction lays the groundwork for an in-depth examination of the transformative shifts in the treatment landscape, key segmentation insights, and regional as well as corporate competitive dynamics that are defining the market. By presenting an analysis that spans from macro trends to nuanced segmentation factors, this summary serves as a strategic guide designed to empower decision-makers with the intelligence necessary to enhance treatment outcomes and foster innovation in the field of CIPN.

Transformative Shifts in the CIPN Treatment Landscape

Recent years have witnessed transformative shifts that are fundamentally altering the approach to CIPN management. Acute challenges in chemotherapy and subsequent peripheral neuropathy have catalyzed a surge in research and development, resulting in a notable transition towards personalized and multi-disciplinary treatment approaches. Historically, CIPN was managed largely through symptomatic relief with limited targeted therapies. However, the integration of emerging research findings and technological advancements has led to the development of more intricately tailored interventions.

Innovative non-pharmacological treatments have become increasingly recognized for their ability to enhance patient recovery. Techniques such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation are steadily gaining ground as viable alternatives or complements to conventional pharmacological measures. Alongside these strategies, a refined focus on pharmacological treatments including anticonvulsants, antidepressants, and opioids has stimulated further debate on efficacy, safety, and patient suitability. The dual emphasis on advanced non-drug modalities and optimized drug regimens marks a clear shift towards a holistic treatment framework.

Recent strategic initiatives have also redefined care pathways by promoting multi-modal therapies that address both the neurological and systemic implications of cancer treatments. Clinicians are increasingly tailoring treatment plans based on a patient's unique profile rather than adhering solely to a standardized protocol. This individualized approach draws on breakthroughs in pharmacological research as well as rehabilitative practices, ensuring that therapeutic interventions are both scientifically sound and aligned with patient-centric care models.

Furthermore, the evolution of digital health tools and wearable monitoring systems is enabling clinicians to track treatment progress in real time. This data-driven insight not only enhances therapeutic precision but also fosters a more proactive engagement with potential side effects. The blend of technological innovation with clinical expertise is clearly redefining the treatment landscape and heralding a new era marked by adaptive, real-time, and individualized patient care.

The forward momentum in CIPN treatment reflects a broader industry trend towards precision medicine and integrated care. Empowered by emerging data and advanced analytics, healthcare providers are now better positioned to navigate the complexities of treatment regimens while proactively addressing the adverse effects associated with chemotherapy. This paradigm shift is not only transforming patient outcomes, but also setting new benchmarks in clinical research and professional practice.

Key Segmentation Insights Driving Market Differentiation

An in-depth segmentation analysis reveals several critical dimensions that are shaping the competitive and strategic landscape of CIPN treatment. The investigation based on treatment type distinguishes approaches into non-pharmacological and pharmacological categories. Within non-pharmacological interventions, modalities such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation demonstrate growing prominence due to their ability to offer alternative avenues for symptom management without the systemic side effects often associated with drug treatments. In parallel, pharmacological interventions continue to evolve, particularly with the increasing adoption of anticonvulsants, antidepressants, and opioids that target the underlying neurological disruptions associated with CIPN.

Further segmentation based on the route of administration introduces an added layer of complexity and personalization in treatment strategies. Traditional oral delivery methods continue to be favored for their convenience, while parenteral routes, including intramuscular and intravenous administration, provide targeted delivery options for patients requiring swift therapeutic intervention. Topical applications also play a vital role by offering localized relief without a broad systemic impact, thereby enhancing the versatility of treatment protocols. This detailed exploration of administration routes underscores the commitment to delivering patient-specific methods that optimize both efficacy and safety.

In addition, the segmentation based on patient age group illustrates a distinct differentiation among adults, geriatrics, and pediatrics. Such demographic segmentation is essential since age-related physiological differences necessitate customized approaches that account for metabolism, tolerance, and overall patient resilience. As patient profiles vary widely, this segmentation framework encourages the development of age-appropriate therapies and highlights the need for more refined clinical guidelines.

Another key dimension is therapy duration, which categorizes interventions into long-term and short-term therapies. This segmentation dimension offers clarity on the sustainability and intensity of care that individual patients may require over the course of their treatment journeys. Strategic insights reveal that long-term therapy solutions are crucial for patients with chronic or refractory symptoms, while short-term therapies are effective in acute management scenarios. By understanding these temporal nuances, stakeholders can better allocate resources and design treatment regimens that align with patient needs and clinical outcomes.

Lastly, differentiation based on the end-user setting, which encompasses home care settings, hospitals, and specialty clinics, allows for the customization of interventions based on the care environment. Treatments that are successfully delivered in a controlled hospital environment may require adjustments when adapted for home care or specialized outpatient clinics. These segmentation insights deeply inform strategic decisions related to market positioning, resource allocation, and network collaborations. Collectively, this layered segmentation approach ensures that treatment strategies not only meet broad clinical objectives but are also finely tuned to the diverse needs of a heterogeneous patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation. The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, and Opioids.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Patient Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy.

Based on End-User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Regional Insights: Market Trends Across Key Geographies

An examination of the global landscape reveals that regional trends are central to understanding the evolving market dynamics in CIPN treatment. In the Americas, robust healthcare infrastructure and active investment in cutting-edge research form the bedrock of patient care innovation, driving a substantial uptake of both pharmacological and non-pharmacological treatments. The region's commitment to integrating novel clinical interventions with traditional treatment paradigms has set a benchmark in patient-centered care.

Across Europe, the Middle East and Africa, market dynamics are deeply influenced by ongoing regulatory reforms and increasing investments in medical research. The collaboration between regional academic institutions and healthcare providers is fostering a progressive environment that supports innovative clinical practices. The emphasis on comprehensive patient management through diversified therapeutic channels, along with the modernization of healthcare delivery systems, is markedly impacting clinical outcomes.

Asia-Pacific continues to emerge as a pivotal growth driver with a strong focus on rapid technological adoption and customized healthcare solutions. Increasing public and private investments in state-of-the-art medical infrastructure are catalyzing the development of advanced treatment practices that cater to the unique needs of its diverse population. Market trends in this region underscore a significant commitment to research, as well as the integration of digital health solutions, which is facilitating a seamless blend of traditional and innovative treatment methodologies.

The regional analysis elucidates the need for localized strategies that account for both economic and cultural factors. Each geographic zone offers distinct opportunities and challenges, thereby necessitating tailored approaches that respect local market conditions while leveraging global clinical insights. Industry stakeholders can draw on these regional insights to optimize growth strategies, enhance clinical collaborations, and ultimately, advance the overall standard of care in CIPN treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Evaluating Key Industry Players

Within the competitive landscape, several key companies have emerged as frontrunners in CIPN treatment innovation. These industry leaders, including AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., and Asahi Kasei Corporation, have been instrumental in propelling the research, development, and commercialization of breakthrough therapeutic solutions. Further contributions come from Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eisai Inc., all of which have demonstrated a steadfast commitment to advancing clinical care in this arena.

Other notable players such as F. Hoffmann-La Roche Ltd and GlaxoSmithKline PLC have leveraged extensive research and robust global networks to introduce both innovative drug compounds and supportive non-pharmacological interventions. The strategic initiatives pursued by Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, and Heron Therapeutics, Inc. have provided additional momentum to the market by focusing on patient-centric treatment design and precision medicine approaches. Ipsen Pharma, Kyowa Kirin Co., Ltd., and Merck & Co., Inc. also play pivotal roles, leveraging cutting-edge research to enhance the efficacy of existing treatment paradigms.

Contributions from Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, and Regeneron Pharmaceuticals, Inc. further underscore the importance of cross-collaborative efforts in addressing complex clinical challenges. Leading international pharmaceutical companies such as Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc. are also key players, with their rigorous research and adaptive clinical strategies helping to shape the future of CIPN treatment. The strategic interplay between these companies is fostering a dynamic ecosystem that continuously refines treatment protocols, enhances patient outcomes, and promotes sustainable clinical innovation across the global market.

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, Heron Therapeutics, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders

Leaders in the healthcare and pharmaceutical sectors are advised to adopt a multi-faceted strategic approach to navigate the evolving CIPN treatment landscape effectively. One recommendation is to invest in robust research and development initiatives that blend groundbreaking clinical trials with real-world evidence. By supporting translational research, organizations can bridge the gap between innovative theory and practical application, thereby ensuring that novel therapies are both effective and accessible.

Another key recommendation is to foster strong partnerships between academic institutions, research organizations, and clinical practitioners. Collaborative efforts that unite diverse areas of expertise can provide the synergies necessary to propel the development of both pharmacological and non-pharmacological treatment options. Furthermore, digitization and advanced data analytics should be embraced to facilitate patient-specific treatment planning, monitor outcomes more accurately, and drive continuous process improvements across the care continuum.

Industry leaders should also consider adopting flexible regulatory strategies that allow for quicker adaptation to new clinical data and technological advancements. Proactive engagement with regulatory bodies can smooth the path to market for emerging therapies, ensuring that groundbreaking treatments reach patients with minimal delays. Additionally, an emphasis on market education and awareness, through initiatives that communicate the benefits and limitations of different treatment modalities, can help healthcare providers integrate new approaches into mainstream clinical practice more seamlessly.

Finally, it is critical to allocate sufficient resources towards enhancing cross-functional expertise within organizations. By cultivating teams that are well-versed in both clinical and commercial aspects, companies can better anticipate market shifts, tailor strategies to evolving patient needs, and ultimately drive long-term value creation. Industry leaders are encouraged to evaluate their current portfolios, reassess strategic priorities, and invest in innovation centers that can serve as incubators for next-generation therapeutic solutions.

Comprehensive Summary and Forward-Looking Perspective

In summary, the analysis presented in this report highlights the multifaceted and evolving nature of CIPN treatment. From the integration of novel non-pharmacological techniques to the advancement of pharmacological interventions, the landscape is clearly defined by a dynamic interplay between innovation and patient-centered care. Detailed segmentation analysis across treatment types, routes of administration, patient age groups, therapy duration, and end-user settings articulates how personalized and adaptable care models are essential for addressing the challenges inherent in managing chemotherapy induced peripheral neuropathy.

Regional insights further cement the role of localized strategies in maximizing treatment efficacy across distinct geographic markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. These regions not only embody diverse healthcare ecosystems but also offer unique opportunities for customization and sustainable growth. Furthermore, the competitive landscape-bolstered by the innovative efforts of leading companies such as AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, and other industry giants-reinforces the importance of cross-collaborative research and strategic partnerships in propelling the future of CIPN treatments.

This comprehensive summary provides a clear and actionable roadmap for industry stakeholders, urging them to harness the power of emerging technologies, foster collaborative research, and remain agile in the face of evolving clinical demands. The confluence of meticulous segmentation insights, regional market dynamics, and corporate innovations collectively serves as a testament to the sector's potential to transform patient care and chart new territories in the treatment of chemotherapy induced peripheral neuropathy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Growing awareness about chemotherapy induced peripheral neuropathy among healthcare providers
      • 5.1.1.3. Surge in government funding for oncology research worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug development processes and research and development activities
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of ergonomic wearables tailored to patients experiencing peripheral neuropathy symptoms
      • 5.1.3.2. Expanding AI technology utilization in developing predictive models for neuropathy risk assessment
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in neuropathic mechanisms for treatment post-chemotherapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing preferences for anticonvulsants and antidepressants due to their dual function in stabilizing nerve activity
    • 5.2.2. End User: Expanding utilization of CIPN in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Treatments
    • 6.2.1. Acupuncture
    • 6.2.2. Physical Therapy
    • 6.2.3. Transcutaneous Electrical Nerve Stimulation
  • 6.3. Pharmacological Treatments
    • 6.3.1. Anticonvulsants
    • 6.3.2. Antidepressants
    • 6.3.3. Opioids

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
    • 7.3.1. Intramuscular
    • 7.3.2. Intravenous
  • 7.4. Topical

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Geriatrics
  • 8.4. Pediatrics

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

  • 9.1. Introduction
  • 9.2. Long-Term Therapy
  • 9.3. Short-Term Therapy

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. NYU Pain Research Center Receives NIH Grant to study chemotherapy-related pain
    • 14.3.2. FDA cleared Artelo Biosciences' IND application for ART26.12
    • 14.3.3. Serpin Pharma and HekaBio's strategic partnership centers on developing SP163M
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AlgoTherapeutix
  • 3. Amgen Inc.
  • 4. Array BioPharma Inc. by Pfizer Inc.
  • 5. Artelo Biosciences, Inc.
  • 6. Asahi Kasei Corporation
  • 7. Astellas Pharma Inc.
  • 8. Bexion Pharmaceuticals, Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eisai Inc.
  • 11. F. Hoffmann-La Roche Ltd
  • 12. GlaxoSmithKline PLC
  • 13. Glenmark Pharmaceuticals Ltd.
  • 14. Grunenthal GmbH
  • 15. Heron Therapeutics, Inc.
  • 16. Ipsen Pharma
  • 17. Kyowa Kirin Co., Ltd.
  • 18. Merck & Co., Inc.
  • 19. Neuralace Medical
  • 20. Novartis AG
  • 21. Regenacy Pharmaceuticals LLC
  • 22. Regeneron Pharmaceuticals, Inc.
  • 23. Sanofi S.A.
  • 24. Serpin Pharma, LLC
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Veloxis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY LONG-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SHORT-TERM THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY THERAPY DURATION, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY TR